Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
52 week high this morning > .057
Theemost informative post today! Let's go GDVM
Trump stated he voted for Governor DeSantis. Trump would never vote for a Rino.
The Biden administration should allow oil companies to pump oil in USA. Chevron and other large oil producers have the best, cleanest, and most environmentally safe pumping and refining operations in the USA. +++++ it would create 1000's of high paying jobs.
The Biden administration should allow oil companies to pump oil in USA. Chevron and other large oil producers have the best, cleanest, and most environmentally safe pumping and refining operations in the USA. +++++ it would create 1000's of high paying jobs.
The United States eased its oil sanctions on Venezuela on Saturday as it authorized Chevron to resume pumping crude oil in the Latin American country and export it to the U.S.
This decision allows Chevron, the second-largest U.S. oil company, to continue working on existing projects in Venezuela through a license, which could be canceled by the U.S. at any time, that lasts six months and will be automatically renewed afterwards on a monthly basis, Reuters reported.
I am looking forward to the merger happening this week. The anticipation volume has already grown over last several sessions. We may break $2.00 before the Wednesday merger date in my opinion.
Very busy holiday wekend for me! Your best bet is to research and let us know. TY.
MIT scientists invent technology to replace broken genes or upload new ones
The researchers behind the new gene editing technique also founded the secretive Watertown biotech company Tome Biosciences.
Researchers at the Massachusetts Institute of Technology have developed a new gene editing technology that they say can “drag-and-drop” large sequences of DNA into the human genome.
The molecular tool gives scientists a new way to completely replace broken genes, paving the way to potential cures for diseases such as cystic fibrosis. It could also be used to install several new genes at once, a trick researchers could employ to supercharge immune cells to fight cancer.
The gene editing tool, dubbed PASTE, was invented by Omar Abudayyeh and Jonathan Gootenberg, former pupils of CRISPR gene editing inventor Feng Zhang, who now run their own joint lab at MIT’s McGovern Institute for Brain Research. A paper describing the technology was published in the journal Nature Biotechnology on Thursday.
This is a major innovation,” said Maura McGrail, a biologist who uses gene editing to study brain development and diseases in animal models at Iowa State University. “It really opens up our ability to modify the genome in ways that can be useful for biomedical research as well as gene therapy.”
Such treatments are at least a few years away from being tested in people. So far, the technology has only been tested in human cells grown in a petri dish and in lab mice.
But biotech investors have already lined up to get a stake in the technology and related approaches. Cambridge-based Prime Medicine, Somerville-based Tessera Therapeutics, and Watertown-based Tome Biosciences — founded by Abudayyeh and Gootenberg last year — are all working on technologies that aim to add new genes or replace faulty ones to treat disease.
These firms, and others in earlier stages, are developing a third generation of technologies based on CRISPR gene editing — the revolutionary tool invented just over a decade ago that empowered biologists to manipulate DNA with ease and precision. Multiple Boston companies are testing experimental therapies based on earlier generations of CRISPR in clinical trials.
The first generation of CRISPR tools relied on a bacterial enzyme called Cas9 to cut DNA at specific sites in the genome, a method that can be used to shut down disease-causing genes. Scientists can also use Cas9 to create an opening to slot in a new gene, but that approach is inefficient and prone to introduce unwanted, and potentially dangerous, mutations.
A second generation of tools, known as base editors, can swap a single letter in the genetic code for another, which can correct typos responsible for inherited diseases. But many diseases are caused by several different genetic mutations, and creating base editing therapies for all of them is unrealistic.
The third generation of gene editing promises to overcome these limitations with tools and techniques that can tackle a wide variety of diseases more safely and efficiently. The methods go by many names. Prime calls it prime editing, Tessera calls it gene writing, and Tome calls it gene insertion. All of them use complex molecular machines, made from natural enzymes that are tweaked and stitched together, to add or replace DNA at precise locations in the human genome.
“We now have several technologies to solve a problem that not that long ago had zero solutions,” said Marc Güell, a synthetic biologist at Pompeu Fabra University in Spain who cofounded Integra Therapeutics in Barcelona to develop his own gene writing technology.
The field is quickly becoming one of the most competitive and secretive sectors of the biotech industry. Experts say that many of these gene writing technologies have similarities, but because many of the companies are shy on the details of their approaches, it is hard to draw direct comparisons.
Tome, the company founded by Abudayyeh and Gootenberg, is developing “programmable gene insertion,” according to its website, language that mirrors the description of the PASTE. But Abudayyeh and Gootenberg declined to confirm that Tome is using the technology, and the company didn’t respond to a request for comment.
The newly published study reveals that a core part of the PASTE technology is an enzyme called an integrase, used by some viruses to sneak their own genes into bacteria. In nature, these enzymes only insert viral genes at specific segments of DNA that function like molecular landing pads. That restriction has made it difficult for scientists to repurpose integrases as a tool for inserting genes into human genomes.
Abudayyeh and Gootenberg sought to overcome that problem by combing the integrase with two other enzymes that collaborate to lay out a landing pad for the integrase at the exact spot in the genome where researchers want to insert the therapeutic piece of DNA.
It’s impressive work, there’s no question about it,” said Erik Sontheimer, a gene editing researcher and vice chair of the RNA Therapeutics Institute at UMass Chan Medical School. New methods for precisely inserting DNA into the genome is “something everybody wants” in the field, he added. Sontheimer is on Tessera’s scientific advisory board.
Two of the three enzymes used in the PASTE technique are the same ones used in the original prime editing technique developed by David Liu, a researcher at the Broad Institute of MIT and Harvard, which can be used to add dozens to hundreds of letters of DNA code into a genome.
Liu’s 2019 paper first describing prime editing showed it could add a landing pad for an integrase. In a 2021 paper, his lab showed that a prime editing could be paired with an integrase to insert DNA over 5,000 letters long into human genomes. The “only notable difference” with PASTE is that the prime editor and integrase are fused, rather than separate pieces, Liu said in an email.
Some researchers told the Globe that PASTE was essentially a new iteration of prime editing rather than a wholly new technology. Abudayyeh and Gootenberg acknowledged that PASTE builds on prime editing, but emphasized that it required a lot of engineering to get all three enzymes to work together. They also said that their approach can be used to add much larger pieces of DNA — up to 36,000 letters long — than prime editing.
Yet the PASTE technique was only 2.5 percent effective at integrating a new gene into liver cells in mice. Sontheimer said that means there’s a lot of room for improvement, but noted that other gene editing technologies also debuted with low success rates that have since improved.
This is just the first attempt,” he said. “Once you establish your baseline, then you tweak, you optimize, you turn as many knobs as you can possibly access, and those numbers go up.”
Chuck Connors > The Rifleman:
Although Connors was a fan of baseball, he joined the Boston Celtics of the newly formed Basketball Association of America after World War II. Connors became the first player to break a backboard, shattering the glass with a simple shot during the warm up of the first home game. (The glass backboard wasn't installed properly.)
Connors left the Celtics to join the Brooklyn Dodgers in 1949. He only played one game with the team, but joined the Chicago Cubs in 1951 as the team's first baseman.
After jumping from sport to sport, Connors perhaps realized he wasn't cut out to be a professional athlete. Before landing the lead on The Rifleman in 1959, Connors was a character actor who appeared in more than 50 film and TV roles.
MICT up 7% @ 1.29 > volume 1,070,000 > TMNA up 1% @ .80 > volume 13, 750 <
More on battery malfunction: Tesla Inc. is recalling about 80,000 cars in China due to software and seat-belt issues, days after U.S. regulators asked the company to recall hundreds of thousands of vehicles.
The electric-car maker, the second largest in China by sales, has filed its recall plan to the State Administration for Market Regulation, the Chinese regulator said Friday.
The recall involves 67,698 imported Model S and Model X cars, which have "software problems" that may lead to battery malfunction. Tesla is also recalling 2,736 imported Model 3 cars and 10,127 of such vehicles made in China. The company cited seat-belt issues for these vehicles, according to China's top market watchdog.
Tesla's recall in China came after the National Highway Traffic Safety Administration in the U.S. last week recalled more than 300,000 Tesla vehicles due to potential taillight failures.
MICT @ 1.32 > new 52 week high!
MICT @ 1.29
Multiple 52 week highs today!
Definitely a different cultural business function I can't relate to.
" If we take Tingo's projected FY 2022 earnings estimate ( $ 470 million net profit) and divide by the outstanding shares after the close of the merger ( around 520 million ) we get $ .90 share , thus making MICT' s earnings per share even higher than it current price. If we multiply this by the fintech average PE ratio of 7.5 times, we get $6.75 > This all means that by November 30, an .80 stock will have a fair value $6.75 nearly 750% increase." >>>>> According to Magpie Securities
" If we take Tingo's projected FY 2022 earnings estimate ( $ 470 million net profit) and divide by the outstanding shares after the close of the merger ( around 520 million ) we get $ .90 share , thus making MICT' s earnings per share even higher than it current price. If we multiply this by the fintech average PE ratio of 7.5 times, we get $6.75 > This all means that by November 30, an .80 stock will have a fair value $6.75 nearly 750% increase." >>>>> According to Magpie Securities
MICT share price up daily. Volume now over 1 million. TMNA share price down again.
1.20 > Heavy volume ! Getting closer to merger.
MICT @ 1.18
The "Market Data " and "Level 2" on right side of screen is vacant. Obviously the change now is about 7 or 8 tabs to use to get trading data on the right side of screen when you are looking at a stock symbol.
MICT @ 1.12
Why remove relative content! The 3 year stock chart for each equity and recent news has disappeared .Charts & PR news are always on right side column. Is this a temporary issue?
The 3 year stock chart for each equity and recent news has disappeared later this afternoon. Charts are always on right side column. Is this a temporary issue?
Kari Lake would probably have done the same if she was elected governor.
Well, Volume for TMNA is 9700. VOLUME for MICT is 667,000 @ closing bell.
MICT @ 1.10 up 15% > anyday merger announcement forthcoming!
Last months SEC 424B4 shelf placement should announce closing with today's masive volume. > Should run hard into closing bell.
COSM
I am telling you again, MICT is the merger gaining momo. Forget the OTC nonsense.
Holy chitoly! ..... Say it ain't so Sammy Sosa!
COSM
Merger happening any day > MICT is a great $$$$$ opportunity.
.985
Getting closer to merger. MICT up last 3 sessions.
NO, I created the board this morning. The institutions doubled their holdings. The tutes did well!
IMGO: But, tough luck for anybody who DIDN'T own this YESTERDAY, right???? (I.e., just another big morning GAPPER --- then sliding SIDEWAYS in price all day long. Did ya have this YESTERDAY, Capt. C-O-24???)
Imago BioSciences Stock Surges. It's Being Bought by Merck. -- Barrons.com
7:29 am ET November 21, 2022 (Dow Jones) Print
By Angela Palumbo
Merck announced Monday it would buy biopharmaceutical company Imago BioSciences in a deal valued at $1.35 billion.
Pharmaceuticals giant Merck (ticker: MRK) will pay $36 in cash per share for Imago (IMG), which is roughly double Imago's closing price of $17.40 a share on Friday.
"This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology," said Merck Chief Executive Robert Davis in a news release.
Hematology is the branch of medicine that focuses on the study of blood diseases. Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of several bone marrow diseases.
Merck's acquisition of Imago is expected to close in the first quarter of 2023.
Imago stock soared 105% to $35.65 in premarket trading on Monday. Merck stock was flat in the premarket session at $104.21 a share.
Write to Angela Palumbo at angela.palumbo@dowjones.com
(END) Dow Jones Newswires
November 21, 2022 07:29 ET (12:29 GMT)
Imago BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It focuses on providing treatment for patients with cancer and bone marrow diseases. The Company’s lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company’s product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The Company also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. It tests bomedemstat in mouse models of MPNs as a single agent.
After many speech errors, mispronunciations,
apparent Freudian slips, rumors began to swirl that President Biden may be dyslexic.
At a press conference the following month, one journalist found the courage to ask "Mr. President, is there any truth to the current rumor that you are, in fact, dyslexic?"
To which he emphatically replied, "ON!"
A Tesla burst into flames on a Pennsylvania highway on Tuesday after a large piece of debris became lodged underneath it. The car fire ended up reducing the electric vehicle to a pile of scrap metal and ash. Luckily the car’s owners and their dog escaped unscathed.
Pennsylvania state police said the Tesla was traveling west on the highway when it caught fire, according to a report by WTAJ, which added that one lane ended up being restricted for some time as crews put out the fire.
Michelle and Bob, the couple who were driving their Tesla Model S on a road trip to Yarmouth, Massachusetts, said they had just brought the car home last Monday.
What allegedly caused the fire was a large piece of debris that was in the middle of the road, which the couple was unable to avoid, their daughter said. From there, the electric vehicle started to smoke once the debris was underneath it.
After they pulled over and got out of their car, it immediately caught fire. The couple and their dog, Coco, escaped unscathed.
Firefighting crews responded to the scene, where they spent nearly two hours and approximately 12,000 gallons of water to extinguish the blaze, given that the vehicle’s lithium-ion battery kept reigniting.
The Columbia Volunteer Fire Company, which was also present at the scene, said they believe this was the first Tesla-related fire reported in the area.
Photos from the fire’s aftermath shared by WTAJ show that the Tesla was completely unrecognizable, and reduced to a pile of scrap metal and ash.
Fires involving electric vehicles are notoriously difficult to put out.
Last month, electric vehicles caught on fire in Florida after becoming waterlogged during Hurricane Ian, giving firefighters “a new challenge” they “haven’t faced before,” according to one Florida official.
In a letter to the National Highway Traffic Safety Administration (NHTSA) requesting information on the fire risks created by saltwater mixing with the batteries of electric vehicles, Florida Chief Financial Officer and State Fire Marshal Jimmy Patronis said that he “saw with my own eyes an EV continuously ignite, and continually reignite, as fireteams doused the vehicle with tens-of-thousands of gallons of water.”
https://www.breitbart.com/tech/2022/11/18/elon-musks-other-company-tesla-bursts-into-flames-on-pennsylvania-highway/
May see $5.00 / share next week. Bitcoin dropping in AH.